Core Insights - The Agfa-Gevaert Group reported stable adjusted EBITDA in Q1 2025 compared to Q1 2024, with improved sales mix and effective cost control offsetting declines in traditional film markets [1][5][10]. Financial Performance - Total revenue decreased by 3.2% from €250 million in Q1 2024 to €242 million in Q1 2025 [4][10]. - Adjusted EBITDA remained stable at €2 million, representing 0.9% of revenue, up from 0.7% in Q1 2024 [4][10]. - The net loss for the period was €20 million, slightly improved from a loss of €21 million in Q1 2024 [4][10]. Division Performance HealthCare IT - Revenue increased by 12.0% to €57 million, with adjusted EBITDA rising from €1.3 million to €5.0 million [2][9]. - The division saw a 63% increase in rolling order intake over 12 months, with a significant share from new customers and cloud-related contracts [11]. - Gross profit margin improved from 43.8% to 47.9% [11]. Digital Print & Chemicals - Revenue grew by 5.8% to €97 million, with adjusted EBITDA increasing from €1.0 million to €2.3 million [13][17]. - Ink sales rose by 16%, although equipment sales were affected by a weaker investment climate [17]. Radiology Solutions - Revenue declined by 15.6% to €73 million, with adjusted EBITDA dropping to -€4.5 million [15][16]. - The division faced challenges due to a significant decline in medical film markets, particularly in China [5][10]. Contractor Operations - Revenue decreased by 29.1% to €15 million, with adjusted EBITDA down by 30.6% [18]. Outlook - The company expects continued strong performance from growth engines in 2025, with a stronger second half anticipated due to seasonal factors [8][10]. - Cost optimization measures for traditional film activities are expected to yield initial savings in the second half of 2025 [1][5].